Developer docs
API playgroundTry for free, no card

Search company profiles

ZYUS

Full company profile

uuid0000f9s

Namestring
ZYUS
Legal namestring
ZYUS Life Sciences Corporation
Websiteurl
zyus.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

ZYUS Life Sciences Corporation is a publicly traded clinical-stage biopharmaceutical company headquartered in Saskatoon, Saskatchewan, Canada, listed on the TSX Venture Exchange under ticker ZYUS. Founded in 2018, the company develops proprietary, non-opioid, non-intoxicating cannabinoid-based pharmaceutical drug candidates targeting pain management indications where the current standard of care relies heavily on opioid analgesics. Its lead asset is Trichomylin®, a proprietary softgel capsule drug candidate under clinical evaluation in the Phase 2a UTOPIA-1 trial (NCT06533657) for moderate to severe cancer-related pain, with preliminary data (Jan 2026) showing reductions in daily pain, pain interference, pain severity and opioid dosing with no serious drug-related adverse events. A second drug candidate based on a Cannabichromene (CBC) formulation targets neuropathic pain conditions including diabetic and cancer-related neuropathies, supported by the issuance of U.S. Patent No. 12,616,704 in May 2026 (the company's second U.S. pain management patent), with IND-enabling studies completed.

The company's business model combines two distinct streams: a direct-to-consumer exempt market medical cannabis operation in Canada via the zyus.ca storefront (selling cannabinoid formulations to registered patients and caregivers with a Medical Document Form), and pre-revenue pharmaceutical drug development awaiting regulatory approval. Distribution is currently single-country (Canada), with future pharmaceutical commercialization expected post-regulatory approval. In June 2026, the company announced a strategic realignment discontinuing international business development and winding down international legal entities to refocus resources on core U.S./Canadian drug development priorities, alongside the departure of long-tenured CSIO Keith Carpenter.

With 51-100 employees, no commercial pharmaceutical product, and capital raised primarily through small private placements and insider-supported debt (notably a C$1.5 million loan from independent director Wayne Brownlee in October 2025 and a C$2 million revolving facility from CEO Brenton H. Zettl), ZYUS operates as an early-stage clinical biotech dependent on continued capital access. ZYUS is also covered by Stifel GMP analyst Justin Keywood on the sell-side and reports audited results through SEDAR+ as a TSXV-listed reporting issuer.

Short descriptiontext

ZYUS Life Sciences Corporation is a clinical-stage Canadian biopharmaceutical company developing proprietary non-opioid, non-intoxicating cannabinoid-based drug candidates (Trichomylin® and a CBC formulation) for cancer-related and neuropathic pain, while selling exempt market medical cannabis in Canada via zyus.ca.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSaskatoon, Canada
HQ citystring
Saskatoon
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid therapeutics, non-opioid pain management, clinical-stage biopharmaceutical, medical cannabis products, oncology pain research
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Pharmacies and Drug Retailers456110
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Clinical-Stage Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical cannabis product sales (exempt market)
TypeTransaction Fee
Description

ZYUS Life Sciences Corporation and its subsidiaries sell exempt market cannabinoid formulations and medical cannabis products in Canada through the zyus.ca commercial website to registered patients and caregivers, generating transactional product revenue.

zyus.com
2Future pharmaceutical drug commercialization (pre-revenue)
TypeLicensing Royalties
Description

Currently pre-revenue on the pharmaceutical pipeline. Future revenue expected from commercialization of non-opioid cannabinoid-based prescription drug candidates (Trichomylin®, CBC formulation) targeting regulatory approval for pain management indications in oncology and neuropathic pain.

zyus.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1LIFE / non-brokered private placement units at C$0.63 per unit
ModelOtherBilling cadencePay-as-you-go
Notes

Up to 11,111,111 units at C$0.63 per unit in the non-brokered private placement launched February 2026 to raise up to C$7 million; first tranche of 451,269 units at C$0.63 each raised approximately C$284,300.

newswire.ca
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 record
1Trichomylin
Description

ZYUS's lead pharmaceutical product candidate - softgel capsules being evaluated in the Phase 2a UTOPIA-1 trial for cancer-related pain and in development for neuropathic pain conditions including diabetic and cancer-related neuropathies; a novel non-opioid, non-intoxicating cannabinoid-based formulation.

prnewswire.com
Core offering1 text field

ZYUS Life Sciences Corporation is a clinical-stage biopharmaceutical company developing proprietary, non-opioid, non-intoxicating cannabinoid-based drug candidates for pain management. Its lead asset, Trichomylin® softgel capsules, is being evaluated in the Phase 2a UTOPIA-1 trial for moderate to severe cancer-related pain, alongside a second Cannabichromene (CBC) formulation drug candidate targeting neuropathic pain. The company also generates current revenue from selling exempt market medical cannabis formulations in Canada directly to registered patients through the zyus.ca online storefront.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2a UTOPIA-1 trial preliminary data (first 25% of enrolled patients) showed reductions in average daily pain, pain interference, and pain severity, as well as reduced opioid dosing for breakthrough cancer pain, with no serious adverse events related to the drug.
+3 more records
Product overview1 text field

ZYUS Life Sciences Corporation is a single clinical-stage pharmaceutical company built around a unified non-opioid pain management pipeline, rather than a platform-plus-modules architecture. Its core offering consists of the Trichomylin® softgel capsules lead drug candidate (evaluated in the Phase 2a UTOPIA-1 trial and previously in the Phase 1 Z-TRI-10001 trial) and a second Cannabichromene (CBC) formulation drug candidate for neuropathic pain, supplemented by commercial Exempt Market Formulations distributed via the zyus.ca online store under the Canadian Cannabis Act. The Trichomylin® and CBC assets together form the proprietary drug development portfolio, while ZYUS.ca functions as the company's patient-facing commercial channel for currently approved medical cannabis products.

Product and service3 records
1Trichomylin® Softgel Capsules
CategoryClinical-stage pharmaceutical drug candidate
Description

ZYUS's lead pharmaceutical drug candidate, a proprietary non-opioid, non-intoxicating cannabinoid-based softgel capsule being evaluated for moderate to severe cancer-related pain and intended for non-opioid pain management in oncology and related indications.

2Cannabichromene (CBC) Formulation for Pain Management
CategoryClinical-stage pharmaceutical drug candidate
Description

ZYUS's second pharmaceutical drug candidate, a novel non-intoxicating Cannabichromene (CBC) formulation covered by U.S. Patent No. 12,616,704, in IND-enabling studies targeting neuropathic pain conditions including diabetic and cancer-related neuropathies.

3Exempt Market Medical Cannabis Formulations
CategoryMedical cannabis (exempt market)
Description

Cannabinoid-based medical cannabis formulations sold under Canada's exempt market framework through the zyus.ca online storefront to registered Canadian patients and caregivers who hold a Medical Document Form from a health care practitioner, generating current transactional product revenue for the company.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ZYUS is conducting the Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients with moderate to severe cancer-related pain. The trial is registered on clinicaltrials.gov as NCT06533657 and is led by Chief Medical Officer Dr. Julie Stakiw. Dr. Stakiw commented on the preliminary results in the January 8, 2026 press release.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Jazz Pharmaceuticals owns Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug, establishing the regulatory pathway ZYUS is targeting. As a profitable specialty pharma with established cannabinoid commercialization infrastructure, it is the most relevant comparable for cannabinoid-pharma execution and BD optionality.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing cannabinoid-based therapies (including rare disease and pain/epidermolysis bullosa indications). Comparable to ZYUS as a small-cap cannabinoid drug developer pursuing FDA-regulated indications.

TypeBroad incumbent
Description

Global pharmaceutical leader with a substantial pain management portfolio and large R&D budget actively pursuing non-opioid alternatives. Represents both the competitive threat and the potential BD/licensing counterparty for ZYUS's cannabinoid pain candidates.

TypeEmerging player
Description

Canadian-licensed medical cannabis producer with a portfolio of medical cannabis products distributed through its patient platform. Comparable as a Canadian medical cannabis operator, though without ZYUS's clinical-stage pharmaceutical pipeline.

TypeEmerging player
Description

Major Canadian cannabis producer with a medical cannabis platform (Spectrum Therapeutics) and historical cannabinoid pharmaceutical research initiatives. Adjacent peer in medical cannabis with broader scale and brand reach than ZYUS.

TypeDirect peer
Description

Clinical-stage pharma historically focused on cannabinoid-derived therapeutics (lenabasum) for inflammatory and fibrotic diseases. Direct competitor in the cannabinoid-pharma category, sharing similar regulatory pathway and small-cap clinical-development risk profile.

7Tetra Bio-Pharma
TypeDirect peer
Description

Canadian clinical-stage pharmaceutical company developing cannabinoid-based prescription drugs for pain and oncology indications. Closest direct Canadian peer to ZYUS with overlapping cannabinoid pain pipeline and similar regulatory approach.

8Tilray Brands
TypeEmerging player
Description

Large Canadian cannabis company with a medical cannabis division selling pharmaceutical-grade products and pursuing cannabinoid-based pharmaceutical opportunities. Comparable as a competitor in the medical cannabis and cannabinoid pharma space, though substantially larger and more diversified than ZYUS.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZYUS

Clinical-Stage Biopharmaceutical Therapeuticszyus.com

ZYUS Life Sciences Corporation is a clinical-stage Canadian biopharmaceutical company developing proprietary non-opioid, non-intoxicating cannabinoid-based drug candidates (Trichomylin® and a CBC formulation) for cancer-related and neuropathic pain, while selling exempt market medical cannabis in Canada via zyus.ca.

What ZYUS does

ZYUS Life Sciences Corporation is a publicly traded clinical-stage biopharmaceutical company headquartered in Saskatoon, Saskatchewan, Canada, listed on the TSX Venture Exchange under ticker ZYUS. Founded in 2018, the company develops proprietary, non-opioid, non-intoxicating cannabinoid-based pharmaceutical drug candidates targeting pain management indications where the current standard of care relies heavily on opioid analgesics. Its lead asset is Trichomylin®, a proprietary softgel capsule drug candidate under clinical evaluation in the Phase 2a UTOPIA-1 trial (NCT06533657) for moderate to severe cancer-related pain, with preliminary data (Jan 2026) showing reductions in daily pain, pain interference, pain severity and opioid dosing with no serious drug-related adverse events. A second drug candidate based on a Cannabichromene (CBC) formulation targets neuropathic pain conditions including diabetic and cancer-related neuropathies, supported by the issuance of U.S. Patent No. 12,616,704 in May 2026 (the company's second U.S. pain management patent), with IND-enabling studies completed.

The company's business model combines two distinct streams: a direct-to-consumer exempt market medical cannabis operation in Canada via the zyus.ca storefront (selling cannabinoid formulations to registered patients and caregivers with a Medical Document Form), and pre-revenue pharmaceutical drug development awaiting regulatory approval. Distribution is currently single-country (Canada), with future pharmaceutical commercialization expected post-regulatory approval. In June 2026, the company announced a strategic realignment discontinuing international business development and winding down international legal entities to refocus resources on core U.S./Canadian drug development priorities, alongside the departure of long-tenured CSIO Keith Carpenter.

With 51-100 employees, no commercial pharmaceutical product, and capital raised primarily through small private placements and insider-supported debt (notably a C$1.5 million loan from independent director Wayne Brownlee in October 2025 and a C$2 million revolving facility from CEO Brenton H. Zettl), ZYUS operates as an early-stage clinical biotech dependent on continued capital access. ZYUS is also covered by Stifel GMP analyst Justin Keywood on the sell-side and reports audited results through SEDAR+ as a TSXV-listed reporting issuer.

ZYUS firmographics

Firmographics
Name
ZYUS
Legal name
ZYUS Life Sciences Corporation
Website
https://zyus.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
ZYUS Life Sciences Corporation is a clinical-stage Canadian biopharmaceutical company developing proprietary non-opioid, non-intoxicating cannabinoid-based drug candidates (Trichomylin® and a CBC formulation) for cancer-related and neuropathic pain, while selling exempt market medical cannabis in Canada via zyus.ca.
Ownership category
akta.pro rank

ZYUS industry classification

Industry
Product category
Clinical-Stage Biopharmaceutical Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmacies and Drug Retailers (456110)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)

Keywords

  • Cannabinoid therapeutics
  • Non-opioid pain management
  • Clinical-stage biopharmaceutical
  • Medical cannabis products
  • Oncology pain research

Where ZYUS is headquartered

Location

Headquarters

HQ city
Saskatoon
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

ZYUS business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Medical cannabis product sales (exempt market): ZYUS Life Sciences Corporation and its subsidiaries sell exempt market cannabinoid formulations and medical cannabis products in Canada through the zyus.ca commercial website to registered patients and caregivers, generating transactional product revenue.
  2. Future pharmaceutical drug commercialization (pre-revenue): Currently pre-revenue on the pharmaceutical pipeline. Future revenue expected from commercialization of non-opioid cannabinoid-based prescription drug candidates (Trichomylin®, CBC formulation) targeting regulatory approval for pain management indications in oncology and neuropathic pain.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLIFE / non-brokered private placement units at C$0.63 per unit

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

ZYUS product offering

Product offering

Core offering

ZYUS Life Sciences Corporation is a clinical-stage biopharmaceutical company developing proprietary, non-opioid, non-intoxicating cannabinoid-based drug candidates for pain management. Its lead asset, Trichomylin® softgel capsules, is being evaluated in the Phase 2a UTOPIA-1 trial for moderate to severe cancer-related pain, alongside a second Cannabichromene (CBC) formulation drug candidate targeting neuropathic pain. The company also generates current revenue from selling exempt market medical cannabis formulations in Canada directly to registered patients through the zyus.ca online storefront.

Product overview

ZYUS Life Sciences Corporation is a single clinical-stage pharmaceutical company built around a unified non-opioid pain management pipeline, rather than a platform-plus-modules architecture. Its core offering consists of the Trichomylin® softgel capsules lead drug candidate (evaluated in the Phase 2a UTOPIA-1 trial and previously in the Phase 1 Z-TRI-10001 trial) and a second Cannabichromene (CBC) formulation drug candidate for neuropathic pain, supplemented by commercial Exempt Market Formulations distributed via the zyus.ca online store under the Canadian Cannabis Act. The Trichomylin® and CBC assets together form the proprietary drug development portfolio, while ZYUS.ca functions as the company's patient-facing commercial channel for currently approved medical cannabis products.

Differentiator

Problem solved

Functional benefit

Brands

  • Trichomylin: ZYUS's lead pharmaceutical product candidate - softgel capsules being evaluated in the Phase 2a UTOPIA-1 trial for cancer-related pain and in development for neuropathic pain conditions including diabetic and cancer-related neuropathies; a novel non-opioid, non-intoxicating cannabinoid-based formulation.

Products and services

  • Trichomylin® Softgel Capsules ZYUS's lead pharmaceutical drug candidate, a proprietary non-opioid, non-intoxicating cannabinoid-based softgel capsule being evaluated for moderate to severe cancer-related pain and intended for non-opioid pain management in oncology and related indications.
  • Cannabichromene (CBC) Formulation for Pain Management ZYUS's second pharmaceutical drug candidate, a novel non-intoxicating Cannabichromene (CBC) formulation covered by U.S. Patent No. 12,616,704, in IND-enabling studies targeting neuropathic pain conditions including diabetic and cancer-related neuropathies.
  • Exempt Market Medical Cannabis Formulations Cannabinoid-based medical cannabis formulations sold under Canada's exempt market framework through the zyus.ca online storefront to registered Canadian patients and caregivers who hold a Medical Document Form from a health care practitioner, generating current transactional product revenue for the company.

Quantifiable outcome

  • Phase 2a UTOPIA-1 trial preliminary data (first 25% of enrolled patients) showed reductions in average daily pain, pain interference, and pain severity, as well as reduced opioid dosing for breakthrough cancer pain, with no serious adverse events related to the drug.
  • +3 more outcomes

Companies that use ZYUS

Customer profile

Segments3 records

Ideal customer profiles3 records

ZYUS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

ZYUS partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Clinical trial sites and investigators (Phase 2a UTOPIA-1 trial, NCT06533657)coreStrategic or Co-development PartnerZYUS is conducting the Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients with moderate to severe cancer-related pain. The trial is registered on clinicaltrials.gov as NCT06533657 and is led by Chief Medical Officer Dr. Julie Stakiw. Dr. Stakiw commented on the preliminary results in the January 8, 2026 press release.

Scale indicators13 records

Recent moves7 records

Expansion highlights3 records

ZYUS competitors and assessment

Company assessment

Broad incumbents

  • Jazz Pharmaceuticals: Jazz Pharmaceuticals owns Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug, establishing the regulatory pathway ZYUS is targeting. As a profitable specialty pharma with established cannabinoid commercialization infrastructure, it is the most relevant comparable for cannabinoid-pharma execution and BD optionality.
  • Pfizer: Global pharmaceutical leader with a substantial pain management portfolio and large R&D budget actively pursuing non-opioid alternatives. Represents both the competitive threat and the potential BD/licensing counterparty for ZYUS's cannabinoid pain candidates.

Direct peers

  • InMed Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based therapies (including rare disease and pain/epidermolysis bullosa indications). Comparable to ZYUS as a small-cap cannabinoid drug developer pursuing FDA-regulated indications.
  • Corbus Pharmaceuticals: Clinical-stage pharma historically focused on cannabinoid-derived therapeutics (lenabasum) for inflammatory and fibrotic diseases. Direct competitor in the cannabinoid-pharma category, sharing similar regulatory pathway and small-cap clinical-development risk profile.
  • Tetra Bio-Pharma: Canadian clinical-stage pharmaceutical company developing cannabinoid-based prescription drugs for pain and oncology indications. Closest direct Canadian peer to ZYUS with overlapping cannabinoid pain pipeline and similar regulatory approach.

Emerging players

  • Aurora Cannabis: Canadian-licensed medical cannabis producer with a portfolio of medical cannabis products distributed through its patient platform. Comparable as a Canadian medical cannabis operator, though without ZYUS's clinical-stage pharmaceutical pipeline.
  • Canopy Growth: Major Canadian cannabis producer with a medical cannabis platform (Spectrum Therapeutics) and historical cannabinoid pharmaceutical research initiatives. Adjacent peer in medical cannabis with broader scale and brand reach than ZYUS.
  • Tilray Brands: Large Canadian cannabis company with a medical cannabis division selling pharmaceutical-grade products and pursuing cannabinoid-based pharmaceutical opportunities. Comparable as a competitor in the medical cannabis and cannabinoid pharma space, though substantially larger and more diversified than ZYUS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ZYUS social profiles

Digital presence

ZYUS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZYUS leadership team

Management profile

Number of profiles

Profiles9 records

ZYUS subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ZYUS funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZYUS M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZYUS

What does ZYUS do?

ZYUS Life Sciences Corporation is a clinical-stage biopharmaceutical company developing proprietary, non-opioid, non-intoxicating cannabinoid-based drug candidates for pain management. Its lead asset, Trichomylin® softgel capsules, is being evaluated in the Phase 2a UTOPIA-1 trial for moderate to severe cancer-related pain, alongside a second Cannabichromene (CBC) formulation drug candidate targeting neuropathic pain. The company also generates current revenue from selling exempt market medical cannabis formulations in Canada directly to registered patients through the zyus.ca online storefront.

Is ZYUS a public or private company?

ZYUS is a public company. It is classified as public and is currently operating.

When was ZYUS founded?

ZYUS was founded in 2018. It employs 51 to 100 people.

Where is ZYUS based?

ZYUS is headquartered in Saskatoon, Canada, in the North America region.

How does ZYUS make money?

Two revenue lines are on record. Medical cannabis product sales (exempt market) is the primary driver. The others are future pharmaceutical drug commercialization (pre-revenue).

Who are ZYUS's main competitors?

Broad incumbents on record are Jazz Pharmaceuticals and Pfizer. Direct peers are InMed Pharmaceuticals, Corbus Pharmaceuticals and Tetra Bio-Pharma. Emerging players are Aurora Cannabis, Canopy Growth and Tilray Brands.

Does ZYUS have an API?

No public API is recorded for ZYUS.

What industry is ZYUS in?

ZYUS's product category is Clinical-Stage Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of CRANAFAB, Medical Cannabis Dispensaries. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewZYUS Life Sciences Corporation (ZYUS) Closes C$50K Insider Unit TrancheZYUS Life Sciences issued 111,110 units at C$0.45 each, raising C$50,000 from insiders. Combined proceeds from two tranches are about $0.25M, well below the C$3.0M offering maximum. The company expects another tranche shortly.NewswireZYUS Life Sciences Announces Closing of Second Tranche of Non-Brokered Unit Offering Private PlacementZYUS Life Sciences closed its second tranche of a non-brokered private placement, issuing 111,110 units at C$0.45 each for C$50,000 in gross proceeds. The company expects to close an additional tranche shortly, with proceeds for general corporate and working capital.The future of tradingZYUS Life Sciences Raises C$ 200,000 in First Tranche of Private PlacementZyus Life Sciences closed its first tranche of a non-brokered private placement on Oct. 21, 2026, raising CAD 200,000. Insiders purchased all 444,444 units at CAD 0.45 each, with proceeds for general corporate and working capital. A second tranche is expected to close shortly.TradingViewZYUS Life Sciences Corporation (ZYUS) Closes C$200K First Tranche of Unit OfferingZYUS Life Sciences closed its first tranche of a non-brokered private placement, raising C$200K via 444,444 units at C$0.45 with warrants at C$0.59 for 24 months. Insiders purchased all units, and a larger follow-on toward C$3.0M is expected, pending TSXV final approval.TradingViewZYUS Life Sciences Announces Closing of First Tranche of Non-Brokered Unit Offering Private PlacementZYUS Life Sciences closed its first tranche of a non-brokered private placement, issuing 444,444 units at C$0.45 each for C$200,000 in gross proceeds. The units consist of one share and one-half warrant, with proceeds for general corporate and working capital. The company expects to close an additional tranche shortly.NewswireZYUS Life Sciences Announces Closing of First Tranche of Non-Brokered Unit Offering Private PlacementZYUS Life Sciences completed its first tranche of a non-brokered private placement, issuing 444,444 units at C$0.45 each for C$200,000 in gross proceeds. The units, priced at C$0.45, include warrants exercisable at C$0.59, and proceeds will fund general corporate and working capital. The company expects to close an additional tranche shortly.NewswireZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced CancerZYUS Life Sciences announced positive topline results from its Phase 2a UTOPIA-1 trial of Trichomylin softgel capsules in 11 patients with advanced cancer pain. The trial showed 91% titration success, no serious adverse events, and a signal of reduced rescue opioid use. The company plans to present results at MIPCC 2026 and advance to larger trials with opioid reduction as a co-primary endpoint.NewswireZYUS Life Sciences Corporation Announces Planned Release Date for Phase 2a Clinical Trial Results, Annual General Meeting Results and Change in Audit Committee ChairZYUS Life Sciences announced it will release Phase 2a UTOPIA-1 trial results on September 30, 2026, and reported AGM results including director elections and auditor appointment. Wayne Brownlee was appointed Audit Committee Chair, replacing John L. Knowles, who became Interim CFO.NewswireZYUS Life Sciences Corporation Provides General Business Update and Announces Changes in Executive LeadershipZYUS Life Sciences announced a business update and leadership changes effective September 14, 2026, appointing John Knowles as Interim CFO. The company expects to release topline results from its Phase 2a UTOPIA-1 trial by end of Q3 or early Q4 2026, with pain reduction and opioid-sparing as primary and key secondary endpoints.NewswireZYUS Life Sciences Announces Closing of Debt FinancingZYUS Life Sciences closed an unsecured debt financing of CAD$50,000 on September 11, 2026, issuing a promissory note with 15% annual interest maturing December 10, 2026. Proceeds will be used for general working capital.